Company Overview
NanoViricides, Inc. operates as a clinical stage nano-biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics designed to combat viral infections. The enterprise functions within the healthcare sector, specifically the biotechnology industry, positioning it as a developer of specialized drug candidates rather than a manufacturer of broad-spectrum consumer health products. The company maintains a market capitalization of $19.58M and employs a workforce of 7 individuals to execute its research and development initiatives. These valuation and employment figures indicate that NanoViricides, Inc. is a micro-cap entity with a limited operational footprint, suggesting that its current financial resources are heavily concentrated on advancing specific pipeline assets like the NV-387 drug candidate for RSV and influenza indications through phase 1a/1b human clinical trials.
Financial Health
The company reported Net Income of $-8,318,441 and EBITDA of $-7,776,407 for the trailing twelve months, while Revenue remains unquantified in available public data, resulting in a Revenue figure marked as N/A. The substantial gap between the reported Net Income of $-8,318,441 and the EBITDA of $-7,776,407 reveals a significant impact from non-operating expenses or interest costs, alongside the absence of revenue to offset these outflows. Free Cash Flow stands at $-4,385,204, indicating that the company is currently burning cash at a rate that limits its financial flexibility for expansion or unexpected market shifts. All three key margin metrics—the Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which reflects a stage of development where costs vastly outweigh any generated sales, leading to a lack of profitability in the traditional sense. The company holds Cash of $5.15M with Debt listed as N/A, creating a scenario where liquidity assets significantly exceed liabilities, though the lack of debt data prevents a precise leverage calculation. The Current Ratio is 4.43, a figure that indicates a robust short-term liquidity position capable of covering current obligations more than four times over. Return on Equity is -77.5% and Return on Assets is -44.0%, metrics that reveal management is currently utilizing shareholder and asset capital to generate negative returns, a typical characteristic for clinical-stage biotechnology firms before product commercialization occurs.
Valuation Assessment
The Trailing P/E Ratio is N/A due to negative earnings, while the Forward P/E is -2.59, a divergence that implies the market is pricing in future earnings recovery but acknowledges current profitability is non-existent. The Price to Book ratio is 1.77, indicating that the market values the company at a 77% premium over its net asset book value, potentially reflecting intangible assets like intellectual property or the value of the clinical pipeline. The Price to Sales ratio is N/A and the EV/EBITDA stands at -1.86, suggesting that traditional sales-based valuation models are inapplicable while the negative EV/EBITDA highlights the heavy investment phase of the business model. The 52-week high is $2.23 and the 52-week low is $0.85; without a specific current price provided in the facts, the valuation sits within a range of approximately 171% volatility between the yearly extremes. The Beta is 1.27, which means the stock exhibits higher volatility than the broader market, moving 27% more aggressively than the market index on average during periods of fluctuation.
Growth & Income
Revenue Growth YoY and Earnings Growth YoY are both listed as N/A, meaning historical growth rates cannot be calculated from the available data to compare earnings expansion against revenue expansion. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that all available earnings and cash reserves are reinvested directly into research and development rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms in the clinical stage, prioritizing pipeline advancement over immediate income distribution. The overall growth and income profile is characterized by an absence of current profitability and dividend income, relying entirely on the potential value creation from successful commercialization of the NV-387 drug candidate to shift the company from a cash-burning model to a revenue-generating one.